N/A
Completed N=115
Obtain a Good Blood Glucose Control With the Paradigm Real Time System
Source: ClinicalTrials.gov NCT00441129 ↗Enrolled (actual)
115
Serious AEs
7.0%
Results posted
Dec 2018
Primary outcomePrimary: Difference in HbA1C From Baseline and 6 Months — -0.57; -0.81 percentage of HbA1C
Summary
In this study, subjects with insufficient metabolic control despite optimized basal-bolus injection regimens were randomily assigned to either the Mini- Med Paradigm REAL-Time insulin pump (PRT), an insulin pump that can receive and display CGM data from a separate subcutaneous glucose sensor, or conventional CSII, and compared glycemic outcomes after 6 months.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Difference in HbA1C From Baseline and 6 Months |
-0.57; -0.81 | — |
| SECONDARY Change From Baseline in Mean Blood Glucose Value Calculated From CGMS Recordings. |
-10.8; -30.6 | — |
| SECONDARY Change From Baseline in Total Daily Dose (TDD) |
6.8; 1.5 | — |
Eligibility Criteria
Inclusion Criteria
- Patient has signed informed consent form prior to study entry.
- Patients have been diagnosed with Type 1 DM at least 12 months prior to inclusion.
- Patients should have been received diabetes care from the investigator of each center at least 3 months prior to inclusion.
- Patients have been treated with multiple daily injections and use rapid Insulin Analog for their meal prior to study entry.
- Have an HbA1c value ≥ 8 %.
- Pediatric patients must be aged between 2 and 18 years old and adult patients be aged between 19 and 65 years old.
- Patients must perform at least 3 self-monitoring blood glucose finger-sticks daily.
- Patients from PRT group must be willing to wear sensors and transmitter connected to the pump Paradigm® Real-Time for up to 24 weeks and to change sensors, insulin infusion sets and reservoirs every 3 days (~60 times during the study period ).
- Patients from CSII group must be willing to wear an insulin pump, change insulin infusion sets, and reservoirs every 3 days (~60 times during the study period ).
- Patient is required to use the Paradigm® Real-Time system at least 70% of the time during the study period.
- Patients in both groups are required to wear at the beginning and the end of the study a CGMS for 3 days. and to perform 6 self-monitoring blood glucose finger-sticks daily during the 3 days.
- Patients must be willing to undergo all study procedures, to receive a technical training to understand how to use the Paradigm® Real-Time System or the Insulin Pump depending of the randomization.
- Patients must agree to receive a training on how to adapt their insulin doses to their meals, how to calculate and apply corrective treatment.
Exclusion Criteria
- Hearing or vision impairment so that alarms cannot be recognized.
- Alcohol or drug abuses other than nicotine.
- Allergy to sensor or components of the sensor.
- Allergy to insulin infusion set or components of the insulin infusion set.
- Patient is pregnant or of child-bearing potential during the study.
- Patient does not have a reliable support person or the patient is unwilling to comply with the provisions of the protocol.
- Patients suffering from cancer, heart failure, kidney disease and other chronic debilitating conditions.
- Patients participating in other device or drug studies will be excluded.
- Patients may participate in this study only once.
Data sourced from ClinicalTrials.gov (NCT00441129). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.